Authors
Latest:
Future-Proofing Biopharma Launches Requires Personalizing the Customer ExperienceAs the U.S. economy reopens, engagement with healthcare providers and pharma manufacturers will vary significantly from person to person depending on their comfort level. This article provides insight on how engagement could affect product launches.
Latest:
Future-Proofing Biopharma Launches Requires Personalizing the Customer ExperienceAs the U.S. economy reopens, engagement with healthcare providers and pharma manufacturers will vary significantly from person to person depending on their comfort level. This article provides insight on how engagement could affect product launches.
Latest:
Future-Proofing Biopharma Launches Requires Personalizing the Customer ExperienceAs the U.S. economy reopens, engagement with healthcare providers and pharma manufacturers will vary significantly from person to person depending on their comfort level. This article provides insight on how engagement could affect product launches.
Latest:
Future-Proofing Biopharma Launches Requires Personalizing the Customer ExperienceAs the U.S. economy reopens, engagement with healthcare providers and pharma manufacturers will vary significantly from person to person depending on their comfort level. This article provides insight on how engagement could affect product launches.
Latest:
How to REVAMP Sales and Marketing During a Pandemic for Pharma with Value-Driven ApproachWhile the COVID-19 pandemic has put a halt to in-person selling for pharma companies, it has a created a new opportunity for reps to rethink and adapt to new strategies.
Latest:
3 Digital Trends to Support Your Sales Teams Post-COVID-19As the world determines how best to function in a COVID-19 world, it is all but certain that some level of safety measures will continue for the foreseeable future.
Latest:
How Oncologists Cope with COVID-19The COVID-19 pandemic has created challenges across the entirety of the medical landscape. Oncologists and hematologists are just a few of many healthcare providers (HCPs) that have had to adjust to these challenges on the fly.
Latest:
COVID-19: Expanding Remote Patient Services during LockdownStephanie Hill looks at the efforts made by patient solutions providers in the UK to build and support services outside the hospital environment during the pandemic.
Latest:
Patient Information Labeling and COVID-19In recent months, many pharma businesses have pivoted to entirely new product lines against a backdrop of unprecedented disruption to the supply chain. Gurdip Singh provide pointers to ensure companies are ready to adapt to change.
Latest:
Who Pays for Specialty Medicines?Providers and patients fish for that delicate balance between access and abandonment.
Latest:
Risk-Based Monitoring: From the Road Less Traveled to Productivity SuperhighwayThe latest news on the growing cost of conducting clinical trials is becoming a major concern for company sponsors and trial co-operative groups.
Latest:
One World, Many RegulationsThe ability to compete globally is essential to success in the pharmaceutical industry. The current trend is to establish joint ventures, outsource various stages of the development and production of a single pharma product, and purchase or start an indigenous business in other countries.
Latest:
Decision Making at Digital SpeedIn an era in which companies can forfeit $1 million each day they delay a product launch-and being second can mean failure-pharma executives are under pressure to make risk and opportunity decisions in less time than ever.
Latest:
Communicate With ConfidenceInvestors have lost confidence in the market. Specifically, they have lost confidence in the information coming out of corporate America.
Latest:
Bristol-Myers Squibb Sells Diabetes Business to AstraZenecaBristol-Myers Squibb has agreed to sell its global diabetes business that was part of its collaboration with AstraZeneca for $2.7 billion with potential regulatory- and sales-based milestone payments of up to $1.4 billion and will make royalty payments based on net sales through 2025.
Latest:
Tracking Trial Cost Drivers: The Impact of Comparator Drugs and Co-TherapiesNew research from the Tufts Center for the Study of Drug Development identifies a significant contributor to the rising cost of clinical trials-the first step in meeting a growing strategic imperative to help senior management and the regulatory community craft new approaches to make trials more efficient in delivering results to clinicians and patients.
Latest:
The Truth About E-HealthThe returns are in, and they are not pretty. Janus Funds' billion-dollar investment in WebMD in 2000 now has a net value of roughly ten cents on the dollar, and many observers see WebMD as a winner in their space-whatever that space is now.
Latest:
Medical Affairs: From Info Gatekeeper to Legitimate Value DriverThe role of pharma medical affairs teams is taking on greater importance in the value chain.
Latest:
September 2016: Your Hub is Your Secret Weapon to Improve OutcomesHubs can be the secret weapon to providing customized solutions to the industry-wide challenge of improving patient outcomes.
Latest:
Market Access is Dead: Patient Access is the New Prescription for Healthcare MarketingParadigms change when questions emerge the old paradigm can no longer answer. Market access has become a buzz word as access to markets is as significant a hurdle to product usage as registration itself. I
Latest:
Patients Outcomes Impact (POI™): The Evolution of Measuring Patient-Centered InvestmentMichael Shaw, JD, and Sharon Suchotliff, MPH, from ZS, discuss why measuring impact through a patient-centric lens is a business imperative for life sciences companies. They explore key considerations for a key challenge when thinking about impact for patients in the real world- the compliant measurement of non-promotional activities, results from an early ZS proof of concept to determine Patient Outcomes Impact (POI™) metrics, and discuss what you can do today to advance POI™ at your organization.
Latest:
Promotional Review Committees Shire Sets the Standard on Achieving High Performing TeamsWhat does it take for internal Promotional Review Committees to function at their best and avoid costly mistakes to the company? A leading industry practitioner offers 15 tips for high performing teams.
